Spyre Therapeutics, Inc.
General ticker "SYRE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $16.1B (TTM average)
Spyre Therapeutics, Inc. follows the US Stock Market performance with the rate: 60.2%.
Estimated limits based on current volatility of 1.6%: low 88.06$, high 91.44$
Factors to consider:
- Total employees count: 102 (+56.9%) as of 2025
- Top business risk factors: Inability to raise capital, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Third-party risks
- Current price 104.2% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [16.99$, 44.54$]
- 2026-12-31 to 2027-12-31 estimated range: [10.87$, 30.57$]
Financial Metrics affecting the SYRE estimates:
- Negative: with PPE of -15.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 91.96 > 81.92
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: Investing cash flow per share per price, % of -6.80 <= -4.49
Short-term SYRE quotes
Long-term SYRE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.89MM | $0.00MM | $0.00MM |
| Operating Expenses | $243.19MM | $208.57MM | $209.56MM |
| Operating Income | $-242.30MM | $-208.57MM | $-209.56MM |
| Non-Operating Income | $-96.51MM | $0.60MM | $54.34MM |
| R&D Expense | $89.50MM | $162.79MM | $171.65MM |
| Income(Loss) | $-338.82MM | $-207.97MM | $-155.22MM |
| Taxes | $-0.03MM | $0.05MM | $-0.01MM |
| Net Income(Loss)* | $-338.79MM | $-208.02MM | $-155.20MM |
| Stockholders Equity | $184.02MM | $517.80MM | $715.24MM |
| Assets | $341.86MM | $608.48MM | $777.78MM |
| Operating Cash Flow | $-99.91MM | $-157.41MM | $-169.25MM |
| Investing Cash Flow | $-108.39MM | $-353.29MM | $-143.47MM |
| Financing Cash Flow | $361.08MM | $410.91MM | $309.02MM |
| Earnings Per Share** | $-49.12 | $-4.42 | $-2.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.